ROGERIO DE SOUZA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder
137 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 137
- Unusual cause of wheezing: extrinsic bronchial compression by pulmonary artery aneurysm(2018) FERNANDES, Caio Julio Cesar; JASINOWODOLINSKI, Dany; SOUZA, Rogerio
- Clinical, demographic and functional evaluation of patients with hypersensitivity pneumonitis and their comparison based on current diagnostic criteria(2023) BRIDI, Guilherme Das Posses; SILVA, Bianca Freire Da; CUNHA, Marieta Cabral Amaral Da; QUEIROZ, Douglas Silva; ALVES- JR., Jose Leonidas; SALGE, Joao Marcos; CARVALHO, Celso R. F. De; KAIRALLA, Ronaldo Adib; SOUZA, Rogerio De; BALDI, Bruno Guedes
- Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension(2015) MCLAUGHLIN, Vallerie; CHANNICK, Richard N.; GHOFRANI, Hossein-Ardeschir; LEMARIE, Jean-Christophe; NAEIJE, Robert; PACKER, Milton; SOUZA, Rogerio; TAPSON, Victor F.; TOLSON, Jonathan; HITI, Hikmet Al; MEYER, Gisela; HOEPER, Marius M.The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated. In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (>= 20 mg three times daily) for >= 3 months were randomised (1: 1) to placebo or bosentan (125 mg twice daily). The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening. Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death. Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159). A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58-1.19; p=0.2508). The mean between-treatment difference in 6-min walk distance at 16 weeks was + 21.8 m (95% CI + 5.9-37.8 m; p=0.0106). Except for NT-proBNP, no difference was observed for any other end-point. The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile. In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.
conferenceObject Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial(2013) JANSA, Pavel; CHANNICK, Richard; DELCROIX, Marion; GALIE, Nazzareno; GHOFRANI, Hossein-Ardeschir; HUNCHE, Elke; MEHTA, Sanjay; MITTELHOLZER, Camilla; PULIDO, Tomas; SASTRY, B. K. S.; SITBON, Olivier; SOUZA, Rogerio; TORBICKI, Adam; SIMONNEAU, Gerald; RUBIN, Lewis- Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension(2013) PULIDO, Tomas; ADZERIKHO, Igor; CHANNICK, Richard N.; DELCROIX, Marion; GALIE, Nazzareno; GHOFRANI, Hossein-Ardeschir; JANSA, Pavel; JING, Zhi-Cheng; BRUN, Franck-Olivier Le; MEHTA, Sanjay; MITTELHOLZER, Camilla M.; PERCHENET, Loic; SASTRY, B. K. S.; SITBON, Olivier; SOUZA, Rogerio; TORBICKI, Adam; ZENG, Xiaofeng; RUBIN, Lewis J.; SIMONNEAU, GeraldBackground Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial. Methods We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg. Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry. The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with intravenous or subcutaneous prostanoids, or worsening of pulmonary arterial hypertension. Results A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose. The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001). Worsening of pulmonary arterial hypertension was the most frequent primary end-point event. The effect of macitentan on this end point was observed regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline. Adverse events more frequently associated with macitentan than with placebo were headache, nasopharyngitis, and anemia. Conclusions Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.)
- Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan(2013) CHANNICK, Richard; DELCROIX, Marion; GALIE, Nazzareno; GHOFRANI, Hossein A.; JANSA, Pavel; BRUN, Franck-Olivier Le; MEHTA, Sanjay; PERCHENET, Loic; PULIDO, Tomas; SASTRY, B. K.; SITBON, Olivier; SOUZA, Rogerio; TORBICKI, Adam; RUBIN, Lewis J.; SIMONNEAU, Gerald
- Schistosomiasis and pulmonary hypertension(2011) DOS, Caio Julio Cesar; FERNANDES, Santos; JARDIM, Carlos Viana Poyares; HOVNANIAN, Andre; HOETTE, Susana; MORINAGA, Luciana Kato; SOUZA, RogerioExpert Rev. Respir. Med. 5(5), 675-681 (2011) Schistosomiasis is one of the most prevalent chronic infectious diseases in the world. One of its most severe complications, pulmonary hypertension, occurs in up to 5% of patients with hepatosplenic schistosomiasis. The prevalence of schistosomiasis is so overwhelming that schistosomiasis-associated pulmonary hypertension (Sch-PH) may be the most prevalent cause of pulmonary hypertension around the world. Multiple pathways have been described as potential mechanisms of disease in Sch-PH, such as egg embolism, inflammatory disease or pulmonary blood overflow. The possible physiopathological mechanisms will be discussed in this article, as well the disease's clinical course and response to the treatment available.
conferenceObject NIH Bayesian Score As a Stratification Tool in Sickle Cell Disease - Results from a Single Center Cohort in Brazil(2017) FONSECA, Guilherme Henrique Hencklain; GRACA, Lutu Ima Viana da; SOUZA, Rogerio; SUGANUMA, Liliana Mitie; ROCHA, Vanderson; GUALANDRO, Sandra Fatima- Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit(2021) GARCIA, Marcos Vinicius Fernandes; SOUZA, Rogerio; COSTA, Eduardo Leite Vieira; FERNANDES, Caio Julio Cesar Santos; JARDIM, Carlos Viana Poyares; CARUSO, PedroBackground: Patients with acute decompensation of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) admitted to intensive care unit (ICU) have high in-hospital mortality. We hypothesized that pulmonary hypertension (PH) severity, measured by a simplified version of European Society of Cardiology/European Respiratory Society (ESC/ERS) risk assessment, and the severity of organ dysfunction upon ICU admission, measured by sequential organ failure assessment score (SOFA) were associated with in-hospital mortality in decompensated patients with PAH and CTEPH. We also described clinical and laboratory variables during ICU stay. Methods: Observational study including adults with decompensated PAH or CTEPH with unplanned ICU admission between 2014 and 2019. Multivariate logistic regression models were used to evaluate the association of ESC/ERS risk assessment and SOFA score with in-hospital mortality. ESC/ERS risk assessment and SOFA score were included in a decision tree to predict in-hospital mortality. Results: 73 patients were included. In-hospital mortality was 41.1%. ESC/ERS high-risk group (adjusted odds ratio = 95.52) and SOFA score (adjusted odds ratio = 1.80) were associated with in-hospital mortality. The decision tree identified four groups with in-hospital mortality between 8.1% and 100%. Nonsurvivors had a lower central venous oxygen saturation, higher arterial lactate and higher brain natriuretic peptide in the end of first week in the ICU. Conclusions: High-risk on a simplified version of ERS/ESC risk assessment and SOFA score upon ICU admission are associate with in-hospital mortality. A decision tree based on ESC/ERS risk assessment and SOFA score identifies four groups with in-hospital mortality between 8.1% and 100%.
- Haemodynamic definitions and updated clinical classification of pulmonary hypertension(2019) SIMONNEAU, Gerald; MONTANI, David; CELERMAJER, David S.; DENTON, Christopher P.; GATZOULIS, Michael A.; KROWKA, Michael; WILLIAMS, Paul G.; SOUZA, RogerioSince the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP). 25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0 +/- 3.3 mmHg. Two standard deviations above this mean value would suggest mPAP > 20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance. 3Wood Units in the definition of all forms of pre-capillary PH associated with mPAP > 20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "" pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers"", due to the specific prognostic and management of these patients, and a subgroup "" PAH with overt features of venous/ capillaries (pulmonary veno-occlusive disease/ pulmonary capillary haemangiomatosis) involvement"", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.